J. Safra Sarasin Holding AG Reduces Holdings in Gilead Sciences, Inc. $GILD

J. Safra Sarasin Holding AG lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 721,261 shares of the biopharmaceutical company’s stock after selling 98,142 shares during the period. Gilead Sciences comprises about 1.7% of J. Safra Sarasin Holding AG’s holdings, making the stock its 13th largest position. J. Safra Sarasin Holding AG’s holdings in Gilead Sciences were worth $100,516,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in GILD. Paulson Wealth Management Inc. grew its stake in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares during the last quarter. Essex Financial Services Inc. lifted its stake in Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares during the last quarter. Davidson Trust Co. lifted its stake in Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 74 shares during the last quarter. Alpha Cubed Investments LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the period. Finally, Personal CFO Solutions LLC boosted its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 76 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $129.83 on Monday. Gilead Sciences, Inc. has a 12 month low of $107.75 and a 12 month high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The business has a 50 day simple moving average of $129.78 and a 200-day simple moving average of $135.03. The stock has a market capitalization of $161.19 billion, a PE ratio of 17.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts predict that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,000 shares of company stock valued at $10,824,500 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Citigroup lifted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Royal Bank Of Canada lowered their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Finally, Truist Financial reduced their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Twenty-six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $159.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.